We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Serum Protein Test Can Predict Outcomes for Liver Failure Patients

By LabMedica International staff writers
Posted on 29 Mar 2023
Print article
Image: Testing for a serum protein could speed identification of patients who need liver transplants (Photo courtesy of Pexels)
Image: Testing for a serum protein could speed identification of patients who need liver transplants (Photo courtesy of Pexels)

The leading cause of acute liver failure (ALF) is acetaminophen, although other factors such as prescription medications, herbal supplements, autoimmunity, and viruses like Hepatitis A and B can also result in the condition. While most patients with acetaminophen-induced ALF recover without needing a transplant, the demand for organs far surpasses the supply. As a result, a prognostic tool is required to distinguish patients who are likely to recover from those who are likely to succumb to ALF. Now, new research findings have emerged that could save lives by providing faster and more accurate identification of hospitalized patients who require liver transplants or are likely to recover.

In a collaborative study, a team of researchers, including investigators at Rutgers University (Piscataway, NJ, USA), performed a retrospective analysis of blood samples and medical records of hospitalized ALF patients. Their study revealed that levels of a serum protein called carbamoyl phosphate synthetase 1 (CPS1), which is short-lived but abundant, can accurately predict patient outcomes - whether they will recover or require a transplant. This team of researchers has already established CPS1's potential as a prognostic tool in previous studies. These studies demonstrated that CPS1 is only present in the blood when liver cells rich in CPS1 are damaged by acute hepatotoxicants. Additionally, the protein has a short half-life, meaning that if a patient's liver begins to recover and cell death slows or stops, CPS1 levels in the blood will decrease within hours. This decrease in CPS1 levels is a strong indication that the patient is likely to recover without requiring a transplant.

In the latest study, researchers performed a review of records and samples from 103 patients suffering from acetaminophen-induced liver failure and 167 patients with liver failure caused by other factors. On average, patients from the first group who received liver transplants or passed away within three weeks of hospitalization had approximately double the amount of CPS1 in their blood compared to those who recovered spontaneously. In the second group, patients who died or underwent transplants also had higher CPS1 levels than those who recovered, with levels about a third higher. However, the researchers determined that there was an 11 percent probability that this was a mere coincidence. Importantly, a greater percentage of patients with acetaminophen-induced ALF who required liver transplantation or passed away had higher levels of CPS1 on day 3 compared to day 1 of hospitalization. This increase in CPS1 was observed, but not in other liver enzymes that usually indicate injury. A subsequent study involving a larger sample of patients will aim to validate these findings in an independent cohort and determine if there is a link between CPS1 and ALF outcomes resulting from causes unrelated to acetaminophen. The follow-up study will also examine whether incorporating CPS1 measurements into current prognostic tools for predicting liver-failure outcomes enhances their accuracy, especially during the first few days following a liver failure or as part of daily CPS1 level monitoring during hospitalization.

“We still need to validate these results in more patients to further confirm that CPS1 levels predict ALF from causes other than acetaminophen (Tylenol), but this has the potential to be a highly valuable prognostic and clinical management tool for acetaminophen and other causes of liver failure,” said Bishr Omary, senior vice chancellor for academic affairs and research at Rutgers Biomedical and Health Sciences and senior author of the study.

“Enhanced diagnostics, like CPS1, that allow earlier decision-making regarding the need for liver transplantation and that improve the predictability of outcome would clearly improve the care of patients with ALF,” added Lu Chen, a visiting scholar at the Rutgers Center for Advanced Biotechnology and Medicine.

Related Links:
Rutgers University

New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Luteinizing Hormone Assay
DRG LH-Serum ELISA Kit
New
Typhoid Rapid Test
OnSite Typhoid IgG/IgM Combo Rapid Test

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.